1402946141520601093
A new poll of more than 1,400 people who work in the biotech and pharmaceutical industries reveals a clear consensus: The FDA made a big mistake approving Aduhelm, Biogen's unproven Alzheimer's treatment. https://t.co/WOsaF2ZnnJ
— Axios (@axios) June 10, 2021
